Tech Center 1600 • Art Units: 1624
This examiner grants 85% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18592897 | HETEROCYCLIC COMPOUND AND USE THEREOF | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18426461 | Novel Heteroaryl Aminopropanol Derivatives | Non-Final OA | NOVARTIS AG |
| 18546087 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | Non-Final OA | Hoffmann-La Roche Inc. |
| 18554265 | (S)-3-AMINO-4-(DIFLUOROMETHYLENE)CYCLOHEXENE AND CYCLOHEXANE CARBOXYLIC ACID AND USES THEREOF AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE (hOAT) | Non-Final OA | Northwestern University |
| 18443829 | SPIROCYCLIC COMPOUNDS | Non-Final OA | ASTRAZENECA AB |
| 18289047 | TREATING LIVER DISEASE | Non-Final OA | Regents of the University of Minnesota |
| 18275470 | NLRP3 INFLAMMASOME SMALL-MOLECULE INHIBITOR FOR TREATMENT OF ALZHEIMER'S DISEASE | Non-Final OA | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18354330 | EAAT2 ACTIVATORS AND METHODS OF USING THEREOF | Non-Final OA | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. |
| 17793204 | MULTICYCLIC CARBOCATION AND CARBORADICAL COMPOUNDS AND METHODS OF USE | Non-Final OA | Arizona Board of Regents on Behalf of the University of Arizona |
| 18019771 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18335285 | Acesulfame Potassium Compositions and Processes for Producing Same | Final Rejection | Celanese International Corporation |
| 18335325 | Acesulfame Potassium Compositions and Processes for Producing Same | Final Rejection | Celanese International Corporation |
| 18335296 | Acesulfame Potassium Compositions and Processes for Producing Same | Final Rejection | Celanese International Corporation |
| 18335345 | Acesulfame Potassium Compositions and Processes for Producing Same | Final Rejection | Celanese International Corporation |
| 18613714 | GLP-1 Receptor Agonist and Composition and Use Thereof | Final Rejection | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. |
| 18558245 | OREXIN RECEPTOR AGONISTS AND USES THEREOF | Non-Final OA | JAZZ PHARMACEUTICALS IRELAND LIMITED |
| 18263702 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | Non-Final OA | MEDSHINE DISCOVERY INC. |
| 18526500 | CRYSTALLINE FORMS OF N,N-DIMETHYLTRYPTAMINE AND METHODS OF USING THE SAME | Non-Final OA | Atai Therapeutics, Inc. |
| 18517894 | SALTS OF A PI3Kdelta INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | Non-Final OA | BeiGene Switzerland GmbH |
| 18207401 | BICYCLIC COMPOUND AND USE THEREOF | Non-Final OA | SK BIOPHARMACEUTICALS CO., LTD. |
| 18122780 | BICYCLIC COMPOUND AND USE THEREOF | Non-Final OA | SK BIOPHARMACEUTICALS CO., LTD. |
| 18223443 | CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | FOGHORN THERAPEUTICS INC. |
| 18504848 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | Non-Final OA | EMPATHBIO, INC. |
| 18263870 | FUSED TRICYCLIC CYCLIN-DEPENDENT KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Non-Final OA | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
| 18288711 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Non-Final OA | University College Cardiff Consultants Limited |
| 18556746 | COMPOSITION FOR PREVENTING OR TREATING DISEASES CAUSED BY MITOCHONDRIAL DYSFUNCTION, CONTAINING ISOQUINOLINE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | Non-Final OA | ALTMEDICALCO., LTD. |
| 18556295 | ACID ADDITION SALTS OF (S)-3-(2,5-DIMETHOXY-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE AND (S)-3-(2-METHOXY-5-(METHYLTHIO)-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE, SPECIFIC POLYMORPHS THEREOF AND METHODS FOR THEIR MANUFACTURE | Non-Final OA | LOPHORA APS |
| 18554426 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | Non-Final OA | SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. |
| 18278246 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF STRESS-RELATED DISORDERS | Non-Final OA | NIPPON CHEMIPHAR CO., LTD. |
| 18282934 | PRODRUGS OF KV7 CHANNEL OPENERS | Non-Final OA | Xyzagen, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy